Literature DB >> 10779805

Differential role of Fas/Fas ligand interactions in cytolysis of primary and metastatic colon carcinoma cell lines by human antigen-specific CD8+ CTL.

E S Bergmann-Leitner1, S I Abrams.   

Abstract

We have previously identified mutated ras peptides reflecting the glycine to valine substitution at position 12 as HLA-A2-restricted, CD8+ CTL neo-epitopes. CTL lines produced against these peptide epitopes lysed the HLA-A2+ Ag-bearing SW480 primary colon adenocarcinoma cell line, although IFN-gamma treatment of the targets was necessary to achieve efficient cytotoxicity. Here, we compared the lytic phenotype of the SW480 cell line to its metastatic derivative, SW620, as an in vitro paradigm to further characterize the nature of a HLA class I-restricted, Ag-specific CTL response against neoplastic cell lines of primary and metastatic origin. Although both colon carcinoma cell lines were lysed by these Ag-specific CTL following IFN-gamma pretreatment, the mechanisms of lysis were distinct, which reflected differential levels of sensitivity to the Fas pathway. Whereas IFN-gamma pretreatment rendered SW480 cells sensitive to both Fas-dependent and -independent (perforin) pathways, SW620 cells displayed lytic susceptibility to Fas-independent mechanisms only. Moreover, pretreatment of SW480 cells with the anti-colon cancer agent, 5-fluorouracil (5-FU), led to enhanced Fas and ICAM-1 expression and triggered Ag-specific CTL-mediated lysis via Fas- and perforin-based pathways. In contrast, these phenotypic and functional responses were not observed with SW620 cells. Overall, these data suggested that 1) IFN-gamma and 5-FU may enhance the lytic sensitivity of responsive colon carcinoma cells to immune effector mechanisms, including Fas-induced lysis; 2) the malignant phenotype may associate with resistance to Fas-mediated lysis in response to Ag-specific T cell attack; and 3) if Ag-specific CTL possess diverse lytic capabilities, this may overcome, to some extent, the potential "escape" of Fas-resistant carcinoma cells.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10779805     DOI: 10.4049/jimmunol.164.9.4941

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  10 in total

1.  Anti-idiotype antibody induced cellular immunity in mice transgenic for human carcinoembryonic antigen.

Authors:  Asim Saha; Sunil K Chatterjee; Kenneth A Foon; Malaya Bhattacharya-Chatterjee
Journal:  Immunology       Date:  2006-08       Impact factor: 7.397

2.  Loss of Fas Expression and Function Is Coupled with Colon Cancer Resistance to Immune Checkpoint Inhibitor Immunotherapy.

Authors:  Wei Xiao; Mohammed L Ibrahim; Priscilla S Redd; John D Klement; Chunwan Lu; Dafeng Yang; Natasha M Savage; Kebin Liu
Journal:  Mol Cancer Res       Date:  2018-11-14       Impact factor: 5.852

3.  Impaired CD95 expression predisposes for recurrence in curatively resected colon carcinoma: clinical evidence for immunoselection and CD95L mediated control of minimal residual disease.

Authors:  J Sträter; U Hinz; C Hasel; U Bhanot; G Mechtersheimer; T Lehnert; P Möller
Journal:  Gut       Date:  2005-05       Impact factor: 23.059

4.  Role of apoptosis resistance in immune evasion and metastasis of colorectal cancer.

Authors:  Kebin Liu
Journal:  World J Gastrointest Oncol       Date:  2010-11-15

5.  Dissection of spontaneous cytotoxicity by human intestinal intraepithelial lymphocytes: MIC on colon cancer triggers NKG2D-mediated lysis through Fas ligand.

Authors:  Ellen C Ebert; Veronika Groh
Journal:  Immunology       Date:  2008-02-13       Impact factor: 7.397

Review 6.  Adoptive T cell therapy for cancer in the clinic.

Authors:  Carl H June
Journal:  J Clin Invest       Date:  2007-06       Impact factor: 14.808

7.  miR-153 supports colorectal cancer progression via pleiotropic effects that enhance invasion and chemotherapeutic resistance.

Authors:  Lei Zhang; Karen Pickard; Veronika Jenei; Marc D Bullock; Amanda Bruce; Richard Mitter; Gavin Kelly; Christos Paraskeva; John Strefford; John Primrose; Gareth J Thomas; Graham Packham; Alex H Mirnezami
Journal:  Cancer Res       Date:  2013-08-15       Impact factor: 12.701

8.  A novel function for Cyclin A2: control of cell invasion via RhoA signaling.

Authors:  Nikola Arsic; Nawal Bendris; Marion Peter; Christina Begon-Pescia; Cosette Rebouissou; Gilles Gadéa; Nathalie Bouquier; Frédéric Bibeau; Bénédicte Lemmers; Jean Marie Blanchard
Journal:  J Cell Biol       Date:  2012-01-09       Impact factor: 10.539

9.  Protein phosphatase 2A inactivation induces microsatellite instability, neoantigen production and immune response.

Authors:  Yu-Ting Yen; May Chien; Pei-Yi Wu; Chi-Chang Ho; Chun-Te Ho; Kevin Chih-Yang Huang; Shu-Fen Chiang; K S Clifford Chao; William Tzu-Liang Chen; Shih-Chieh Hung
Journal:  Nat Commun       Date:  2021-12-15       Impact factor: 17.694

10.  The Circular RNA Profiles of Colorectal Tumor Metastatic Cells.

Authors:  Weiqin Jiang; Xingchen Zhang; Qinjie Chu; Sen Lu; Linfu Zhou; Xingang Lu; Chen Liu; Lingfeng Mao; Chuyu Ye; Michael P Timko; Longjiang Fan; Haixing Ju
Journal:  Front Genet       Date:  2018-02-09       Impact factor: 4.599

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.